Serial Molecular Profiling of Low-grade Prostate Cancer to Assess Tumor Upgrading: A Longitudinal Cohort Study.

[1]  J. Brooks,et al.  17-Gene Genomic Prostate Score Test Results in the Canary Prostate Active Surveillance Study (PASS) Cohort. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  K. Macura,et al.  Active Surveillance of Grade Group 1 Prostate Cancer: Long-term Outcomes from a Large Prospective Cohort. , 2020, European urology.

[3]  V. Laudone,et al.  Role of Changes in Magnetic Resonance Imaging or Clinical Stage in Evaluation of Disease Progression for Men with Prostate Cancer on Active Surveillance. , 2019, European urology.

[4]  A. D'Amico,et al.  Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. , 2019, Journal of the National Comprehensive Cancer Network : JNCCN.

[5]  A. D'Amico,et al.  Use of Active Surveillance or Watchful Waiting for Low-Risk Prostate Cancer and Management Trends Across Risk Groups in the United States, 2010-2015 , 2019, JAMA.

[6]  G. Pond,et al.  Active Surveillance Magnetic Resonance Imaging Study (ASIST): Results of a Randomized Multicenter Prospective Trial. , 2019, European urology.

[7]  M. Rubin,et al.  Transcriptomic heterogeneity in multifocal prostate cancer. , 2018, JCI insight.

[8]  D. Margolis,et al.  Targeted Biopsy to Detect Gleason Score Upgrading during Active Surveillance for Men with Low versus Intermediate Risk Prostate Cancer , 2017, The Journal of urology.

[9]  David Gillatt,et al.  10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer. , 2017, The New England journal of medicine.

[10]  K. Macura,et al.  The Role of Multiparametric Magnetic Resonance Imaging/Ultrasound Fusion Biopsy in Active Surveillance. , 2017, European urology.

[11]  Adam D. DePriest,et al.  Intratumoral and Intertumoral Genomic Heterogeneity of Multifocal Localized Prostate Cancer Impacts Molecular Classifications and Genomic Prognosticators. , 2017, European urology.

[12]  Wei Li,et al.  Gleason Score 7 Prostate Cancers Emerge through Branched Evolution of Clonal Gleason Pattern 3 and 4 , 2017, Clinical Cancer Research.

[13]  S. Tomlins,et al.  Molecular Profiling to Determine Clonality of Serial Magnetic Resonance Imaging/Ultrasound Fusion Biopsies from Men on Active Surveillance for Low-Risk Prostate Cancer , 2016, Clinical Cancer Research.

[14]  H. Hricak,et al.  Updated prostate imaging reporting and data system (PIRADS v2) recommendations for the detection of clinically significant prostate cancer using multiparametric MRI: critical evaluation using whole-mount pathology as standard of reference , 2016, European Radiology.

[15]  M. Cooperberg,et al.  Trends in Management for Patients With Localized Prostate Cancer, 1990-2013. , 2015, JAMA.

[16]  Paul D. Williams,et al.  Development and Validation of a Scalable Next-Generation Sequencing System for Assessing Relevant Somatic Variants in Solid Tumors12 , 2015, Neoplasia.

[17]  Danny Vesprini,et al.  Long-term follow-up of a large active surveillance cohort of patients with prostate cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  Geoffrey A. Sonn,et al.  Initial experience with electronic tracking of specific tumor sites in men undergoing active surveillance of prostate cancer. , 2014, Urologic oncology.

[19]  K. Pienta,et al.  Frequent discordance between ERG gene rearrangement and ERG protein expression in a rapid autopsy cohort of patients with lethal, metastatic, castration‐resistant prostate cancer , 2014, The Prostate.

[20]  Christopher D. Brown,et al.  Low-grade prostate cancer diverges early from high grade and metastatic disease , 2014, Cancer science.

[21]  Lurdes Y T Inoue,et al.  Modeling grade progression in an active surveillance study , 2014, Statistics in medicine.

[22]  Jennifer R. Rider,et al.  Gleason grade progression is uncommon. , 2013, Cancer research.

[23]  G. Bubley,et al.  Clonal progression of prostate cancers from Gleason grade 3 to grade 4. , 2013, Cancer research.

[24]  A. Chinnaiyan,et al.  Antibody-based detection of ERG rearrangements in prostate core biopsies, including diagnostically challenging cases: ERG staining in prostate core biopsies. , 2012, Archives of pathology & laboratory medicine.

[25]  Matthew R Cooperberg,et al.  Changes in prostate cancer grade on serial biopsy in men undergoing active surveillance. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  S. Varambally,et al.  Antibody-based detection of ERG rearrangement-positive prostate cancer. , 2010, Neoplasia.

[27]  R. Shah,et al.  Characterization of TMPRSS2-ETS gene aberrations in androgen-independent metastatic prostate cancer. , 2008, Cancer research.

[28]  R. Shah,et al.  Heterogeneity of TMPRSS2 gene rearrangements in multifocal prostate adenocarcinoma: molecular evidence for an independent group of diseases. , 2007, Cancer research.

[29]  M. Terris,et al.  Multiinstitutional validation of the UCSF cancer of the prostate risk assessment for prediction of recurrence after radical prostatectomy , 2006, Cancer.

[30]  Michael Ittmann,et al.  Expression of variant TMPRSS2/ERG fusion messenger RNAs is associated with aggressive prostate cancer. , 2006, Cancer research.

[31]  B. Trock,et al.  Delayed versus immediate surgical intervention and prostate cancer outcome. , 2006, Journal of the National Cancer Institute.

[32]  E. Crawford,et al.  Epidemiology of prostate cancer. , 2003, Urology.

[33]  P. Walsh,et al.  Dedifferentiation of prostate cancer grade with time in men followed expectantly for stage T1c disease. , 2001, The Journal of urology.

[34]  S. Lipsitz,et al.  Variation in the use of active surveillance for low‐risk prostate cancer , 2018, Cancer.

[35]  David C. Miller,et al.  Contemporary use of initial active surveillance among men in Michigan with low-risk prostate cancer. , 2015, European urology.

[36]  A. D'Amico,et al.  NCCN clinical practice guidelines in oncology: prostate cancer. , 2010, Journal of the National Comprehensive Cancer Network : JNCCN.

[37]  Anthony D'Amico,et al.  Prostate cancer. Clinical practice guidelines in oncology. , 2007, Journal of the National Comprehensive Cancer Network : JNCCN.